Obesity-Related Coagulation Activation in Adolescents and Children: A Systematic Review and Meta-Analysis.

Obes RevApr 26, 2026 (epub)
Clinical ResearchHematology

Julia Buchold, Hans-Jonas Meyer, Manuel Florian Struck et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of obesity on coagulation biomarkers in 59,503 individuals, including children and adults. The study found significant elevations in D-dimer, fibrinogen, PAI-1, and ETP levels in both populations, indicating a pro-thrombotic state associated with obesity. Notably, D-dimer levels were elevated by 1.36 in adults and 0.77 in children.

Key findings

  • D-dimer levels were significantly elevated in adults (SMD 1.36) and children (SMD 0.77) with obesity.
  • Fibrinogen levels were markedly higher in adults (SMD 1.17) and children (SMD 1.43) with obesity.
  • PAI-1 showed a pronounced increase in adults (SMD 2.30) and children (SMD 3.54) with obesity.
  • ETP was significantly higher in children (SMD 1.06) and adults (SMD 0.71) with obesity.

Why it matters

Understanding the coagulation changes associated with obesity is crucial for clinicians, as these alterations may increase the risk of thrombotic events. This knowledge can inform monitoring and management strategies in obese patients.

Source

PubMed · PMID 42036302

Published in Obes Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.